EP416 - ECE_1411 - Risk of incident chronic obstructive pulmonary disease in type 2 diabetes treated with SGLT2 inhibitors or GLP-1 receptor agonists vs DPP-4 inhibitors: a Real-World Cohort Study
Patients with type 2 diabetes (T2D) have a higher risk of developing chronic obstructive pulmonary disease (COPD), which is associated with substantial morbidity and mortality. Although sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated...